Adnan Butt

Adnan is a senior biotechnology analyst at RBC Capital Markets. His current coverage universe and research interests encompass cardiology, infectious diseases, neuro-psychiatry, oncology, and ophthalmology, as well as other emerging areas and modalities. Adnan is a member of the Institutional Investor ranked mid and small cap biotechnology team as well as an invited speaker at various industry conferences. Previously, he held positions of increasing responsibility in biotechnology equity research at JPMorgan, where he was a member of the Institutional Investor-ranked biotechnology team, Morgan Stanley and ThinkEquity Partners, covering small to large capitalization companies. Adnan began his career at de Visscher, Olson & Allen, an investment bank and private equity boutique focused on closely held businesses.